Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of St. John's Wort on Rivaroxaban PK/PD
NCT03796377Phase 1Completed
- Sponsor
- Insel Gruppe
- Start
- Feb 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivaroxaban in thromboembolism (2 arms), sponsored by Insel Gruppe. Primary endpoints: Area Under the Curve at 48 hours, Maximal Concentration at 48 hours and 1 more. Started Feb 2019; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT03796377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796377.